

Electronic Acknowledgement Receipt

EFS ID:	2305902
Application Number:	10577834
International Application Number:	
Confirmation Number:	6222
Title of Invention:	Muscarinic acetylcholine receptor antagonists
First Named Inventor/Applicant Name:	Zehong Wan
Customer Number:	20462
Filer:	Dara L. Dinner/Christina Boyer
Filer Authorized By:	Dara L. Dinner
Attorney Docket Number:	PU60574
Receipt Date:	11-OCT-2007
Filing Date:	01-MAY-2006
Time Stamp:	10:49:04
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	IDS.pdf	55298 14446c1f4a4a78e12bf829313b0d401f4ad89640	no	1

Warnings:

Information:					
2	Information Disclosure Statement (IDS) Filed	1449.pdf	165245	no	2
			9f9c2863797c626bb95b5bd3b9716a870c1d04e2		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	wo8705213.pdf	654832	no	21
			4346e92424fe5a85568cb77eef5f06552f6c9b1e		
Warnings:					
Information:					
4	Foreign Reference	gb2242134.pdf	1891363	no	59
			00b32335219f8dcb8671d88218912c07a571bce5		
Warnings:					
Information:					
5	Foreign Reference	gb2178965.pdf	733161	no	13
			f8e221c64f698a6c2d67b0edab671e42542fc474		
Warnings:					
Information:					
6	Foreign Reference	gb2129691.pdf	461307	no	7
			9418a4ff7249a08e7681ed87c34390937d82ce0d		
Warnings:					
Information:					
7	NPL Documents	Brown_History_Basic_Properties.pdf	226196	no	3
			9f3eca4b476751090a8fdece309ed6570a15cb21		
Warnings:					
Information:					
8	NPL Documents	Caulfield_Pharmac_Ther_1993.pdf	5296433	no	61
			65a3bb401e841050232cb2845a301d46897c52c2		
Warnings:					
Information:					
9	NPL Documents	Costello_Amer_J_Physio_1999.pdf	4007893	no	6
			6b30daa2a5fe5fde193a16b041a85e83aab8f70		
Warnings:					
Information:					

10	NPL Documents	Fryer_Jacoby_Am_J_Respir _Crit_Care_Med.pdf	6444167	no	7
			f571db5f7c83d6a9df9b120a48f9c37f69 14e21f		
Warnings:					
Information:					
11	NPL Documents	Fryer_et_al_Life_Sci_1999.p df	460449	no	7
			90a561905ccfe869483ecd3a6d7073eb f4e26abd		
Warnings:					
Information:					
12	NPL Documents	Hedge_et_al_life_sci_1999.p df	576559	no	10
			99955122a7c9762c0a8902ca26eba75 efbd27cb6		
Warnings:					
Information:					
13	NPL Documents	lkeda_2002.pdf	940768	no	7
			16ea3fe68ff7144bf369d668441fb8a3e0 354e05		
Warnings:					
Information:					
14	NPL Documents	Minette_et_al_J_appl_Phys_ 1989.pdf	586565	no	5
			0173644039a5f8e5eb4cfc3396ad783b 4e6e6615		
Warnings:					
Information:					
15	NPL Documents	Oprins_et_al_Annals_NY_Ac ad_Sci_2000.pdf	74628	no	5
			814a66e30eba2d05c0b7082e6fa4e4f0 c49ba49e		
Warnings:					
Information:					
16	Foreign Reference	gb2169265.pdf	392150	no	7
			6ddca74c3a727fa31255d9f85d948cf6d 3ae1b42		
Warnings:					
Information:					
17	Foreign Reference	gb2064336.pdf	295429	no	5
			6caea9e21973e67829093129ae7469f4 22ed5d19		
Warnings:					
Information:					
18	Foreign Reference	EP0069715.pdf	567082	no	16
			5b3ca3f8745df7a4eb428b6f1e1e21e01 4ccb123		
Warnings:					
Information:					

19	NPL Documents	Pauwels_et_al_Am_j_Respir _Crit_Care_Med_2001.pdf	262392	no	21
			f5cd64325393cfeb7031488b4d09300 831b1bb2		
Warnings:					
Information:					
20	NPL Documents	RanAbstract.pdf	17051	no	2
			e8e3acd2c2862e4a2ea4196eb48e4a7 a5f4c639f		
Warnings:					
Information:					
21	NPL Documents	SarauMolPharm1999.pdf	234511	no	7
			fb8c151a8410f833f19eeddc8630315d6 c0b53b0		
Warnings:					
Information:					
22	NPL Documents	VanRossumClear.pdf	831266	no	32
			e28ff1d8331ad379230e3f3955044cc76 e201dd0		
Warnings:					
Information:					
23	NPL Documents	WuAbstract.pdf	10985	no	1
			efd4e20bc7e0dc14a75fe4e7195d34d1 19fb7ae4		
Warnings:					
Information:					
24	NPL Documents	zhang.pdf	1354664	no	9
			a1f6ef37bc11d1d7ba0fe2d064e6d6658 90f217c		
Warnings:					
Information:					
25	NPL Documents	ZirkleJMedPharmChem.pdf	651696	no	9
			439500387535d278bb826d229cb37d9 e195e203d		
Warnings:					
Information:					
26	NPL Documents	ZirkleJMedPharmChempart1 .pdf	389022	no	11
			2791f8e17762c2b44d88fdcd0f194c878 ecb138f		
Warnings:					
Information:					
27	NPL Documents	ZirkleJMedPharmChempart2 .pdf	283573	no	7
			f18350fe53f8a843769488973819e3b5b 74662a6		
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.